Evidence map›Paper›PMID 39724414›Full record

ArticleWorld journal of urology2024

Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series.

Marco Finati, Antonio Fanelli, Francesco Cinelli, Nicola Schiavone, Ugo Giovanni Falagario, Anna Ricapito, Nicola d'Altilia, Richard Naspro, Angelo Porreca, Felice Crocetto and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marco Finati *Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy. marco.finati@gmail.com.ORCID http://orcid.org/0000-0002-7425-1166
Antonio Fanelli *Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Francesco CinelliDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Nicola SchiavoneDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Ugo Giovanni FalagarioDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Anna RicapitoDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Nicola d'AltiliaDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Richard NasproUrology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Angelo PorrecaDepartment of Urology, Humanitas Gavazzeni, Humanitas University, Bergamo, Italy.
Felice CrocettoDepartment of Urology, Federico II University, Napoli, Italy.
Biagio BaroneDepartment of Urology, Federico II University, Napoli, Italy.
Ciro ImbimboDepartment of Urology, Federico II University, Napoli, Italy.
Carlo BettocchiDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Francesca SanguedolceDepartment of Pathology, University of Foggia, Foggia, Italy.
Luigi CormioDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Giuseppe CarrieriDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Gian Maria BusettoDepartment of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to comprehensively evaluate the prognostic value of T1 histo-anatomic substaging (T1a/T1b) for high grade (HG) non-muscle invasive bladder cancer (NMIBC) over a large single-centre cohort. MATERIALS AND

methodsPatients with primary HG T1 NMIBC were identified from our Institutional database, between 2011 and 2022. Data from diagnosis to repeated transurethral resection of bladder tumour (RE-TURBT), bacillus Calmette-Guérin (BCG) treatment and follow-up were collected. Patients were stratified based on histo-anatomic landmark into T1a (invasion above the Muscularis Mucosa-MM) and T1b (into/beyond MM). Kaplan-Meier curves and multivariate Cox regression analyses were used to assess the impact of histo-anatomic substaging on recurrence-free survival (RFS), cancer-specific survival (CSS), and progression-free survival (PFS).

resultsSubstaging was feasible in 88% of cases. The median (IQR) follow-up was 40 (17-72) months. T1b patients had larger initial tumours (> 3 cm: 43.2% vs. 26.1%, p < 0.001), while upstaging to muscle-invasive bladder cancer (MIBC) at RE-TURBT was more frequent in T1b than in T1a (5.9% vs. 1.5%, p = 0.02). T1b patients without BCG induction had worse RFS and PFS (all p ≤ 0.02) compared to T1a, while no differences were observed in patients who received complete BCG induction. At Multivariate analysis, completing at least a BCG induction course was associated with better outcomes across all endpoints.

conclusionsInvasion of the MM in primary T1 NMIBC is associated with a higher risk of upstaging to MIBC. Patients who received full BCG induction had similar outcomes regardless of substaging, whereas T1b patients without BCG induction experienced higher recurrence and progression rates.

Indexed as

Neoplasm InvasivenessNeoplasm StagingUrinary Bladder NeoplasmsAgedBCG VaccineFemaleHumansMaleMiddle AgedNeoplasm GradingNon-Muscle Invasive Bladder NeoplasmsPrognosisRetrospective StudiesSurvival RateTreatment OutcomeBCG VaccineBCG VaccineNon-muscle invasive bladder neoplasmsT1 substagingUrinary bladder neoplasms

Identifiers

PMID39724414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.